<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02212652</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00044789</org_study_id>
    <nct_id>NCT02212652</nct_id>
  </id_info>
  <brief_title>Vitamin D to Improve Nutrition Prior to Bariatric Surgery and Investigate the Relationship With Negative Outcomes</brief_title>
  <acronym>VISTA</acronym>
  <official_title>The Effect of VItamin D Supplementation on Nutritional STatus and Adverse Outcomes in Bariatric Surgery (VISTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bariatric Advantage</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      VISTA is looking to see if vitamin D supplements before bariatric surgery might improve&#xD;
      vitamin D stores, which may help to prevent some complications like infections.&#xD;
&#xD;
      Who can join this research study?&#xD;
&#xD;
        -  Approved to undergo bariatric surgery-Roux-en-Y Gastric Bypass or Vertical Sleeve&#xD;
           Gastrectomy-at the Johns Hopkins Bayview Medical Center&#xD;
&#xD;
        -  18 to 64 years of age&#xD;
&#xD;
        -  BMI of 35 to 49.9 kg/m2&#xD;
&#xD;
        -  VitD insufficient or deficient prior to having surgery&#xD;
&#xD;
      What will happen if a participant chooses to participate in this research study?&#xD;
&#xD;
        -  The participant will be randomly assigned (by chance) to receive either:&#xD;
&#xD;
        -  Standard care plus vitamin D supplements or&#xD;
&#xD;
        -  Standard care plus a placebo (contains no vitamin D)&#xD;
&#xD;
        -  Either would be provided at no cost to the participant&#xD;
&#xD;
        -  The investigators will ask the participant to complete a survey on the day of surgery&#xD;
           regarding supplement use&#xD;
&#xD;
        -  The investigators will follow the participants medical record through the 12 month&#xD;
           follow up clinic visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 2 in 3 American adults are either overweight (BMI 25-29.9 kg/m2) or obese (BMI&#xD;
      30-39.9 kg/m2). The prevalence of obesity, morbid obesity (BMI 40-44.9 kg/m2), and even super&#xD;
      obesity (BMI ≥ 45 kg/m2) are increasing. Obesity is a leading contributor to global mortality&#xD;
      and contributes to the burden of disease associated with diabetes, cardiovascular disease,&#xD;
      musculoskeletal disorders such as osteoarthritis, and some cancers. Morbid obesity reduces&#xD;
      life expectancy by 8 to 10 years, similar to the effect of being a regular cigarette smoker.&#xD;
&#xD;
      Several studies have demonstrated that most obese adults are vitamin D (VitD) insufficient&#xD;
      (&lt;75 nmol/L, 30 ng/ml) or deficient (&lt;50 nmol/L, 20 ng/ml). The inverse relationship between&#xD;
      body mass index (BMI) or body fat mass and VitD status is hypothesized to be due to&#xD;
      sequestration of VitD by adipose tissue, reducing the bioavailability of VitD. The classical&#xD;
      role of VitD is in the maintenance of bone calcification, but more recent research has&#xD;
      elucidated a more varied role for this hormone. Lack of VitD has been associated with&#xD;
      increased susceptibility to infection, autoimmunity, cancer, and chronic disease.&#xD;
&#xD;
      Bariatric surgery is currently the most successful means of long-term weight loss. Since&#xD;
      deficiency in fat-soluble vitamins, such as VitD, is considered a metabolic complication of&#xD;
      bariatric surgery, determining the VitD status of these individuals and perhaps correcting it&#xD;
      prior to surgery may prove greatly beneficial. Potential complications relating to VitD&#xD;
      insufficiency and deficiency include adverse surgical outcomes such as improper wound&#xD;
      healing, infection of the surgical incision, and atrial fibrillation. Since the indications&#xD;
      for bariatric surgery are obesity and obesity-related comorbidities, bariatric surgery&#xD;
      patients are at an increased risk of having an adverse surgical outcome.&#xD;
&#xD;
      The Johns Hopkins Center for Bariatric Surgery (JHCBS) is designated as a Center of&#xD;
      Excellence by the American College of Surgeons. To comply with this designation, the center&#xD;
      must maintain a certain standard of care (SoC) and minimize complication rates. Given the&#xD;
      potential relationship between VitD status and adverse surgical outcomes, the investigators&#xD;
      are currently reviewing pre-operative VitD status (serum 25(OH)D concentration) collected as&#xD;
      routine SoC and investigating the relationship with surgical outcomes under an Institutional&#xD;
      Review Board (IRB) approved protocol (NA_00087502). The investigators findings reveal that&#xD;
      most of bariatric surgery patients are VitD insufficient and deficient pre-operatively. To&#xD;
      date, there is no standard regarding treating these deficiencies pre-operatively and as such&#xD;
      the center does not intervene prior to surgery. A randomized, double-blinded,&#xD;
      placebo-controlled pilot trial is needed to assess the causality of the relationship between&#xD;
      pre-operative VitD status and adverse surgical outcomes in the bariatric surgical patient.&#xD;
&#xD;
      The investigators plan to identify new patients approved for bariatric surgery at the JHCBS.&#xD;
      These patients will be randomized consecutively in a 1:1 ratio to either 30 days of 10,000&#xD;
      International Units (IU) of VitD3 plus SoC or 30 days of placebo plus SoC immediately prior&#xD;
      to surgery. The investigators will monitor these patients for any adverse surgical outcomes,&#xD;
      including wound infection, dehiscence, and prolonged length of hospital stay. The&#xD;
      investigators will also monitor their long-term clinical outcomes such as malnutrition,&#xD;
      weight loss, and resolution of comorbidities at their routine clinic care visit: 2 weeks, 6&#xD;
      weeks, 3 months, 6 months, and 12 months post-operatively. At these visits the patients are&#xD;
      assessed for wound healing, weight loss, nutritional status, and other key markers of health,&#xD;
      such as vital signs.&#xD;
&#xD;
      The investigators aim to determine if 10,000 IU of VitD3 daily for 30 days prior to bariatric&#xD;
      surgery (Roux-en Y Gastric Bypass (RYGB) or Vertical Sleeve Gastrectomy (VSG)) will&#xD;
      significantly increase the VitD status (serum 25(OH)D concentration) and whether the&#xD;
      associated change in VitD status leads to decrease risk of adverse surgical outcomes and/or&#xD;
      improved clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of support resources to complete study appropriately&#xD;
  </why_stopped>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D status as measured by serum 25(OH)D concentration.</measure>
    <time_frame>Up to 12 months after surgery</time_frame>
    <description>Improved post-operative vitamin D status as measured by serum 25(OH)D concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse surgical outcomes (aggregate)</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Adverse surgical outcomes include surgical site infection, wound separation and dehiscence, anastomotic leak, prolonged length of hospital stay (&gt; 3 days), and re-admittance to the hospital within 30 days post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes (aggregate)</measure>
    <time_frame>Up to 12 months after surgery</time_frame>
    <description>Long-term clinical outcomes include wound healing, weight loss, nutritional status, resolution of comorbidities, and other key markers of health, such as vital signs (fever, blood pressure, heart rate, pain, etc.) and return of a regular menstrual cycle.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Vitamin D Insufficiency</condition>
  <arm_group>
    <arm_group_label>Standard of Care plus Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>If randomized to this arm, each participant will receive a 30 day supply of 10,000 IU of VitD3 for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>If randomized to this arm, each participant will receive a 30 day supply of placebo supplements for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>10,000 IU of VitD3 daily (one gel daily)</description>
    <arm_group_label>Standard of Care plus Vitamin D</arm_group_label>
    <other_name>Bariatric Advantage Vitamin D Chewable Gels</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gummy button placebo, which will appear very similar to the vitamin D supplement.</description>
    <arm_group_label>Standard of Care plus Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.</description>
    <arm_group_label>Standard of Care plus Placebo</arm_group_label>
    <arm_group_label>Standard of Care plus Vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients approved for and undergoing clinically indicated bariatric surgery -Roux-en-Y&#xD;
             Gastric Bypass (RYGBP) or Vertical Sleeve Gastrectomy (VSG)&#xD;
&#xD;
          -  18 to 64 years of age&#xD;
&#xD;
          -  BMI of 35 to 49.9 kg/m2&#xD;
&#xD;
          -  VitD insufficient pre-operatively: serum 25(OH)D concentration &lt; 75 nmol/L or 30 ng/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient who does not want to participate in the study&#xD;
&#xD;
          -  Any patient who has dietary restrictions/proscriptions prohibiting ingestion of beef&#xD;
             gelatin&#xD;
&#xD;
          -  Expected poor compliance with the medical regimen&#xD;
&#xD;
          -  Any active medical conditions that could, in the opinion of the investigators,&#xD;
             jeopardize the safety of the subject or the integrity of the study&#xD;
&#xD;
          -  The elective bariatric surgery is cancelled prior to incision by a surgeon for any&#xD;
             reason&#xD;
&#xD;
          -  Pregnancy: The routine standard of care is to determine whether a female patient is&#xD;
             pregnant either by history and/or urinary pregnancy test on the day of surgery. No&#xD;
             additional testing specifically for this study is planned beyond the standard of care.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberley E Steele, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael A. Schweitzer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas H Magnuson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Johns Hopkins Center for Bariatric Surgery</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hopkinsmedicine.org/johns_hopkins_bayview/medical_services/specialty_care/bariatrics/</url>
    <description>The Johns Hopkins Center for Bariatric Surgery</description>
  </link>
  <reference>
    <citation>Quraishi SA, Bittner EA, Blum L, Hutter MM, Camargo CA Jr. Association between preoperative 25-hydroxyvitamin D level and hospital-acquired infections following Roux-en-Y gastric bypass surgery. JAMA Surg. 2014 Feb;149(2):112-8. doi: 10.1001/jamasurg.2013.3176.</citation>
    <PMID>24284777</PMID>
  </reference>
  <reference>
    <citation>Goldner WS, Stoner JA, Lyden E, Thompson J, Taylor K, Larson L, Erickson J, McBride C. Finding the optimal dose of vitamin D following Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial. Obes Surg. 2009 Feb;19(2):173-179. doi: 10.1007/s11695-008-9680-y. Epub 2008 Sep 16.</citation>
    <PMID>18795378</PMID>
  </reference>
  <reference>
    <citation>Lin E, Armstrong-Moore D, Liang Z, Sweeney JF, Torres WE, Ziegler TR, Tangpricha V, Gletsu-Miller N. Contribution of adipose tissue to plasma 25-hydroxyvitamin D concentrations during weight loss following gastric bypass surgery. Obesity (Silver Spring). 2011 Mar;19(3):588-94. doi: 10.1038/oby.2010.239. Epub 2010 Oct 14.</citation>
    <PMID>20948527</PMID>
  </reference>
  <reference>
    <citation>Nguyen S, Baggerly L, French C, Heaney RP, Gorham ED, Garland CF. 25-Hydroxyvitamin D in the range of 20 to 100 ng/mL and incidence of kidney stones. Am J Public Health. 2014 Sep;104(9):1783-7. doi: 10.2105/AJPH.2013.301368. Epub 2013 Oct 17.</citation>
    <PMID>24134366</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bariatric surgery</keyword>
  <keyword>Vitamin D deficiency</keyword>
  <keyword>Vitamin D insufficiency</keyword>
  <keyword>Adverse surgical outcomes</keyword>
  <keyword>Clinical outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02212652
org study id: IRB00044789
nct id: NCT02212652
lead sponsor: 
collaborator: 
has dmc: No
VISTA is looking to see if vitamin D supplements before bariatric surgery might improve
      vitamin D stores, which may help to prevent some complications like infections.

      Who can join this research study?

        -  Approved to undergo bariatric surgery-Roux-en-Y Gastric Bypass or Vertical Sleeve
           Gastrectomy-at the Johns Hopkins Bayview Medical Center

        -  18 to 64 years of age

        -  BMI of 35 to 49.9 kg/m2

        -  VitD insufficient or deficient prior to having surgery

      What will happen if a participant chooses to participate in this research study?

        -  The participant will be randomly assigned (by chance) to receive either:

        -  Standard care plus vitamin D supplements or

        -  Standard care plus a placebo (contains no vitamin D)

        -  Either would be provided at no cost to the participant

        -  The investigators will ask the participant to complete a survey on the day of surgery
           regarding supplement use

        -  The investigators will follow the participants medical record through the 12 month
           follow up clinic visit.
An estimated 2 in 3 American adults are either overweight (BMI 25-29.9 kg/m2) or obese (BMI
      30-39.9 kg/m2). The prevalence of obesity, morbid obesity (BMI 40-44.9 kg/m2), and even super
      obesity (BMI ≥ 45 kg/m2) are increasing. Obesity is a leading contributor to global mortality
      and contributes to the burden of disease associated with diabetes, cardiovascular disease,
      musculoskeletal disorders such as osteoarthritis, and some cancers. Morbid obesity reduces
      life expectancy by 8 to 10 years, similar to the effect of being a regular cigarette smoker.

      Several studies have demonstrated that most obese adults are vitamin D (VitD) insufficient
      (<75 nmol/L, 30 ng/ml) or deficient (<50 nmol/L, 20 ng/ml). The inverse relationship between
      body mass index (BMI) or body fat mass and VitD status is hypothesized to be due to
      sequestration of VitD by adipose tissue, reducing the bioavailability of VitD. The classical
      role of VitD is in the maintenance of bone calcification, but more recent research has
      elucidated a more varied role for this hormone. Lack of VitD has been associated with
      increased susceptibility to infection, autoimmunity, cancer, and chronic disease.

      Bariatric surgery is currently the most successful means of long-term weight loss. Since
      deficiency in fat-soluble vitamins, such as VitD, is considered a metabolic complication of
      bariatric surgery, determining the VitD status of these individuals and perhaps correcting it
      prior to surgery may prove greatly beneficial. Potential complications relating to VitD
      insufficiency and deficiency include adverse surgical outcomes such as improper wound
      healing, infection of the surgical incision, and atrial fibrillation. Since the indications
      for bariatric surgery are obesity and obesity-related comorbidities, bariatric surgery
      patients are at an increased risk of having an adverse surgical outcome.

      The Johns Hopkins Center for Bariatric Surgery (JHCBS) is designated as a Center of
      Excellence by the American College of Surgeons. To comply with this designation, the center
      must maintain a certain standard of care (SoC) and minimize complication rates. Given the
      potential relationship between VitD status and adverse surgical outcomes, the investigators
      are currently reviewing pre-operative VitD status (serum 25(OH)D concentration) collected as
      routine SoC and investigating the relationship with surgical outcomes under an Institutional
      Review Board (IRB) approved protocol (NA_00087502). The investigators findings reveal that
      most of bariatric surgery patients are VitD insufficient and deficient pre-operatively. To
      date, there is no standard regarding treating these deficiencies pre-operatively and as such
      the center does not intervene prior to surgery. A randomized, double-blinded,
      placebo-controlled pilot trial is needed to assess the causality of the relationship between
      pre-operative VitD status and adverse surgical outcomes in the bariatric surgical patient.

      The investigators plan to identify new patients approved for bariatric surgery at the JHCBS.
      These patients will be randomized consecutively in a 1:1 ratio to either 30 days of 10,000
      International Units (IU) of VitD3 plus SoC or 30 days of placebo plus SoC immediately prior
      to surgery. The investigators will monitor these patients for any adverse surgical outcomes,
      including wound infection, dehiscence, and prolonged length of hospital stay. The
      investigators will also monitor their long-term clinical outcomes such as malnutrition,
      weight loss, and resolution of comorbidities at their routine clinic care visit: 2 weeks, 6
      weeks, 3 months, 6 months, and 12 months post-operatively. At these visits the patients are
      assessed for wound healing, weight loss, nutritional status, and other key markers of health,
      such as vital signs.

      The investigators aim to determine if 10,000 IU of VitD3 daily for 30 days prior to bariatric
      surgery (Roux-en Y Gastric Bypass (RYGB) or Vertical Sleeve Gastrectomy (VSG)) will
      significantly increase the VitD status (serum 25(OH)D concentration) and whether the
      associated change in VitD status leads to decrease risk of adverse surgical outcomes and/or
      improved clinical outcomes.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Triple (Participant, Investigator, Outcomes Assessor)
measure: Vitamin D status as measured by serum 25(OH)D concentration.
time frame: Up to 12 months after surgery
description: Improved post-operative vitamin D status as measured by serum 25(OH)D concentration.
measure: Adverse surgical outcomes (aggregate)
time frame: Up to 30 days after surgery
description: Adverse surgical outcomes include surgical site infection, wound separation and dehiscence, anastomotic leak, prolonged length of hospital stay (> 3 days), and re-admittance to the hospital within 30 days post-operatively.
measure: Clinical outcomes (aggregate)
time frame: Up to 12 months after surgery
description: Long-term clinical outcomes include wound healing, weight loss, nutritional status, resolution of comorbidities, and other key markers of health, such as vital signs (fever, blood pressure, heart rate, pain, etc.) and return of a regular menstrual cycle.
arm group label: Standard of Care plus Vitamin D
arm group type: Active Comparator
description: If randomized to this arm, each participant will receive a 30 day supply of 10,000 IU of VitD3 for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
arm group label: Standard of Care plus Placebo
arm group type: Placebo Comparator
description: If randomized to this arm, each participant will receive a 30 day supply of placebo supplements for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
intervention type: Dietary Supplement
intervention name: Vitamin D
description: 10,000 IU of VitD3 daily (one gel daily)
arm group label: Standard of Care plus Vitamin D
other name: Bariatric Advantage Vitamin D Chewable Gels
intervention type: Other
intervention name: Placebo
description: Gummy button placebo, which will appear very similar to the vitamin D supplement.
arm group label: Standard of Care plus Placebo
intervention type: Other
intervention name: Standard of Care
description: Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
arm group label: Standard of Care plus Placebo
arm group label: Standard of Care plus Vitamin D
criteria: 
gender: All
minimum age: 18 Years
maximum age: 64 Years
healthy volunteers: No
last name: Kimberley E Steele, MD, PhD
role: Principal Investigator
affiliation: Johns Hopkins University
last name: Michael A. Schweitzer, MD
role: Study Director
affiliation: Johns Hopkins University
last name: Thomas H Magnuson, MD
role: Study Director
affiliation: Johns Hopkins University
facility: 
country: United States
url: http://www.hopkinsmedicine.org/johns_hopkins_bayview/medical_services/specialty_care/bariatrics/
description: The Johns Hopkins Center for Bariatric Surgery
citation: Quraishi SA, Bittner EA, Blum L, Hutter MM, Camargo CA Jr. Association between preoperative 25-hydroxyvitamin D level and hospital-acquired infections following Roux-en-Y gastric bypass surgery. JAMA Surg. 2014 Feb;149(2):112-8. doi: 10.1001/jamasurg.2013.3176.
PMID: 24284777
citation: Goldner WS, Stoner JA, Lyden E, Thompson J, Taylor K, Larson L, Erickson J, McBride C. Finding the optimal dose of vitamin D following Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial. Obes Surg. 2009 Feb;19(2):173-179. doi: 10.1007/s11695-008-9680-y. Epub 2008 Sep 16.
PMID: 18795378
citation: Lin E, Armstrong-Moore D, Liang Z, Sweeney JF, Torres WE, Ziegler TR, Tangpricha V, Gletsu-Miller N. Contribution of adipose tissue to plasma 25-hydroxyvitamin D concentrations during weight loss following gastric bypass surgery. Obesity (Silver Spring). 2011 Mar;19(3):588-94. doi: 10.1038/oby.2010.239. Epub 2010 Oct 14.
PMID: 20948527
citation: Nguyen S, Baggerly L, French C, Heaney RP, Gorham ED, Garland CF. 25-Hydroxyvitamin D in the range of 20 to 100 ng/mL and incidence of kidney stones. Am J Public Health. 2014 Sep;104(9):1783-7. doi: 10.2105/AJPH.2013.301368. Epub 2013 Oct 17.
PMID: 24134366
responsible party type: Sponsor
mesh term: Vitamin D Deficiency
mesh term: Vitamin D
mesh term: Ergocalciferols
mesh term: Cholecalciferol
mesh term: Vitamins